Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic.

doi:10.1016/j.ebiom.2024.105415

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic.

EBioMedicine - 1 Dec 2024

Akerman Anouschka, Fichter Christina, Milogiannakis Vanessa, Esneau Camille, Silva Mariana Ruiz, Ison Tim, Lopez Joseph A, Naing Zin, Caguicla Joanna, Amatayakul-Chantler Supavadee, Roth Nathan, Manni Sandro, Hauser Thomas, Barnes Thomas, Boss Tino, Condylios Anna, Yeang Malinna, Sato Kenta, Bartlett Nathan N, Darley David, Matthews Gail, Stark Damien J, Promsri Susan, Rawlinson William D, Murrell Benjamin, Kelleher Anthony D, Dwyer Dominic, Sintchenko Vitali, Kok Jen, Ellis Sally, Marris Kelsi, Knight Elizabeth, Hoad Veronic C, Irving David O, Gosbell Iain, Brilot Fabienne, Wood James, Aggarwal Anupriya, Turville Stuart G

Abstract excerpt

BACKGROUND: Continued phenotyping and ongoing molecular epidemiology are important in current and future monitoring of emerging SARS-CoV-2 lineages. Herein we developed pragmatic strategies to track the emergence, spread and phenotype of SARS-CoV-2 variants in Australia in an era of decreasing diagnostic PCR testing and focused cohort-based studies. This was aligned to longitudinal studies that span 4 years of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to Antibodies, Viral

Share to Australia

Share to COVID-19

Share to Longitudinal Studies

Share to Pandemics

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 39549677
DOI: 10.1016/j.ebiom.2024.105415
PMCID: PMC11599457

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemic.PMID 39549677Read ↗

Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemicSemantic proximity Read ↗

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concernSemantic proximity Read ↗

SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of ConcernSemantic proximity Read ↗

Rapid isolation and resolution immune evasion and viral fitness across contemporary SARS-CoV-2 variantsSemantic proximity Read ↗

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sublineages in the face of maturing antibody breadth at the population levelSemantic proximity Read ↗

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population levelSemantic proximity Read ↗

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodiesSemantic proximity Read ↗

Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variantSemantic proximity Read ↗

Limited Cross-Variant Immune Response From SARS-CoV-2 Omicron BA.2 in Naïve But Not Previously Infected OutpatientsSemantic proximity Read ↗

The Longitudinal Analysis of Convergent Antibody VDJ Regions in SARS-CoV-2-Positive Patients Using RNA-SeqSemantic proximity Read ↗

Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents.Semantic proximity Read ↗

Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.